Stay updated on TROPION-Lung07: Dato-DXd vs Pembrolizumab in 1L NSCLC Clinical Trial
Sign up to get notified when there's something new on the TROPION-Lung07: Dato-DXd vs Pembrolizumab in 1L NSCLC Clinical Trial page.

Latest updates to the TROPION-Lung07: Dato-DXd vs Pembrolizumab in 1L NSCLC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe page now shows Revision: v3.6.6 in the release information, replacing Revision: v3.6.5. This indicates a site/software update.SummaryDifference0.0%

- Check15 days agoNo Change Detected
- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedThe page now shows Revision: v3.6.5, replacing v3.6.4, indicating a new build of the site. It is a technical update that does not modify study information or how users interact with the page.SummaryDifference0.0%

- Check44 days agoChange DetectedRevision updated from v3.6.3 to v3.6.4, indicating a minor deployment/update. No content changes are indicated by the data provided.SummaryDifference0.0%

- Check65 days agoChange DetectedThe site footer revision shows v3.6.3, replacing the previous v3.6.2. This indicates a new software release for the ClinicalTrials.gov interface, likely including fixes or enhancements.SummaryDifference0.0%

- Check72 days agoChange DetectedExpanded the study’s location network to 260 sites by adding several new centers (eg Hospital da Luz in Lisbon; Hubei Cancer Hospital in Wuhan; Tianjin Medical University General Hospital; The Second Peoples Hospital of Neijiang; Haikou Peoples Hospital; Saiseikai Matsusaka Municipal Hospital) across multiple countries. The deletions remove Matsusaka Municipal Hospital and Adana Baskent University, and the total location count changes from 254 to 260.SummaryDifference0.5%

- Check87 days agoChange DetectedRecruitment status updated to indicate the study is no longer enrolling, and new navigation/help sections were added while a few header labels were adjusted; these changes mainly affect how users access information rather than altering the trial's design or outcomes.SummaryDifference0.1%

Stay in the know with updates to TROPION-Lung07: Dato-DXd vs Pembrolizumab in 1L NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the TROPION-Lung07: Dato-DXd vs Pembrolizumab in 1L NSCLC Clinical Trial page.